Hello

OpPacli™

Novel chemo for solid cancers
(lung, breast, etc.)

Treat solid cancers well
to be better off
and live for long

A 3B USD opportunity

Problem – Cytotoxic drugs are indispensable components of the anticancer arsenal. Chemo sadly remains a neglected area of oncology research despite its brutal adverse effects and perfectible efficacy - it is there to stay. 16 B USD worth of cytotoxic drugs are administered each year under a maximum tolerated dose regimen; paclitaxel itself (Taxol®, Abraxane®) is a 3 B$ neglected market crying for a radical upgrade.

Solution – OpPacli™ will provide patients with an efficacious and bearable chemo treatment. Silica's versatile chemistry allows our nanocarrier to mend three faults of current treatments by:

  1. sequestering its toxic cargo away from healthy tissues during circulation,
  2. unloading more of the cancer-killing drug in the tumor microenvironment and
  3. exiting the body with minimal impact on the patient.

Treat solid cancers well
to be better off
and live for long

Novel chemotherapy

Pharma in silica, a preclinical-stage pharmaceutical company, develops a bearable, efficacious and affordable chemotherapy for solid cancers.

The OpPacli™ nanocarrier, a nano-sized silica sphere, has been designed to increase the efficacy and reduce the toxicity of chemotherapies used daily to treat certain cancers (annual sales > 3 B USD, growing).

Us, shareholders and scientists, have made a triple wager. We trust that, in 2027, our novel silica-based chemo will:

  • reduce the adverse effects and improve the survival of persons treated for a cancer;
  • be licensed by several pharmaceutical companies;
  • provide the investors wiith a profitable exit.

Production of preclinical and clinical lots in Pharma in silica's NanoLab

First unmet need: lung cancer

Among the deadliest (1,7 M/y)

5-year survival: 26% (advance-stage: 8%)

25%~40% response to immunotherapies

Chemo first choice for patients with low PD-L1 expression

A superior nanocarrier...

Entrapped paclitaxel

Cytotoxic cargo sequestered in the particle's porous network

Silica matrix

Proprietary combination of silanes (regulator-accepted excipients)

Functionality

Surface treatment for stability, stealth in blood, cell internalization, in situ drug release

Add-on ready

Anchoring points for third-party targeting ligands or other useful function

... builds unique value

OpPacli's novel pharmacokinetics

Less drug in healthy tissues, long circulation, more drug to the tumor

lead to novel pharmacodynamics

Reduced adverse effects, increased efficacy

that procure benefits to patient

Extended survival rate, improved quality of life, savings for payer, patient & insurer

and trigger creation of value

Pharma deals, profitable exit

Timeline: well defined path to IND/CTA

2019...
Launch, POCs

Paclitaxel-loaded nanoparticle

Patents filed

Own R&D facility

Innocuity & efficacy demos

2023
2024
Technology

Lead candidate: OpPacli™ • 505 (b) (2)

Continuous flow production with in-process QC

Scaled-up regulatory-compliant CMC

Patents in national phase or issued

CROs recruited

2025
2026
Preclinical studies

4 M CAD round

Comparative murine xenograff studies

Reg. studies (CRO)

IND/CTA filing

Clinical lot production

Development of proprietary prototypes

Intelligence toward pharma partnerships

 
Clinical trial

Phase I/IIa OpPacli™ vs NSCLC (USA/Can)

Basket study - OpPacli vs breast & other solid tumors

Development of novel products

≥ 2027
Inflection point

1st pharma partnership (license & contract manufacturing)

Exit opportunities (M&A & IPO) and/or profitable operations

 
Growth

Early-stage dev. of proprietary products

Additional pharma partnerships

License and contract manufacturing

Own GMP production facility

4 M CAD preclinical round

A 4 M CAD round is on-going.

The first tranche was closed in August 2024 when historical shareholders and new accredited investors brought in 1,5 M$.

This Autumn, participate to the second 2,5 M$ tranche at the same price & conditions, half of which to be matched by IQ.

The capital will be dedicated, for the next 18 months, to:

  1. complete the preclinical studies up to an approved USA/Canada phase I/IIa study for our 3rd generation nano-paclitaxel against Non-Small Cell Lung Carcinoma (NSCLC);
  2. approach pharma partners toward licences and manufacturing contracts;
  3. conduct 3 proofs of concept;
  4. upgrade to clinical standards our in-house production capability.

Exit opportunities 2027

M&A, IPO and/or profitable operations from pharma partnerships

Median upfront payment by pharmas paid in Q1-3 2024: 27 M USD for a phase I license

Invest now

Same conditions & price than 1st tranche

All shares voting and participating

Term sheet, pre-IND package & due diligence reports available upon request

Pharma in silica recruits

Experienced clinicians : phase I/IIa study OpPacli™ vs NSCLC

Solid cancer oncologists, preferably in thoracic oncology • Sensitive to the impact of chemotherapy side effects on the patient experience and healthcare system • Willing to comment the draft clinical program and to share their experience during an exploratory meeting • Eventually, ready to contribute to the clinical study.

Experts in chemotherapy : advisory committee

Motivated by the reduction of chemotherapy side effects • Well-versed in the measurement of patient experience and the pharmaco-economics of chemo • Ideally with experience and/or curiosity for nanocarriers.

Contact

François Arcand
info@pharma-insilica.com

OpPacli™ vs solid cancers

About us

President & cofounder
François Arcand, MBA

Co-founder of Medicago (Québec), CEO of ERA Biotech (Barcelona)

Scientific coordinator
Myriam Laprise-Pelletier, PhD

Nanomedicine research at Université Laval (Québec)

Contact us

info@pharma-insilica.com
2500, Parc-Technologique Blvd
Quebec City (Quebec) G1P 4S6
Canada

Product Development
Sonia Trepanier, PhD

VP, Product Dev., Medicago & Aramis

Business Development
Jean-François Haince, PhD

Oncology R&D/business dev. & tech transfer

Medical Director
(Q1 2025)

Oncologist expert in chemo & early-stage drug development

Experienced management & top tier advisors

Expert chemists, pharmacists & technicians

Strong board of directors & networked investors (AbbVie, Pfizer, Roche, business, manufacturing, chemistry & startup)

News